uBriGene Biosciences completes several hundred million yuan Series C round funding
Summary
uBriGene, with its talented team, abundant industrialization experience, unique technical advantages, and comprehensive facilities and services, has produced leading accomplishments with its partners. Bofeng Hu, Jinshi Investment Vice General Manager, and Director of CLSA Capital said: CGT development has entered a stage of rapid growth in China and globally. We hope that uBriGene will help strengthen the technical know-how and production chain security of this field in China, accelerate the drug application progress for downstream clients, and benefit more Chinese patients, he added.Mr. Yi Zhang, Managing Partner of Huagai Medical Foundation at Yangtze River Delta, said: CGT will become the direction with the most potential of the biomedical development initiatives. Through the rigorous selection of quality projects, CLSA Capital generates superior investment returns for global investors.uBriGene Biosciences Inc. team consists of world-renowned experts.
Funding
Review available funding amount, funding date, investors, and linked company information related to uBriGene Biosciences completes several hundred million yuan Series C round funding in the interactive ISVWorld profile.